Repros Therapeutics Inc. (RPRX)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.070.00 (0.00%)
As of 1:38 PM EDT. Market open.
People also watch:
SNSSTHLDCYCCEBIOOGXI
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open2.09
Prev Close2.07
Bid2.07 x 1300
Ask2.08 x 1900
Day's Range2.06 - 2.12
52wk Range0.80 - 8.12
1y Target EstN/A
Market Cap50.34M
P/E Ratio (ttm)-2.27
Beta0.25
Volume39,477
Avg Vol (3m)348,365
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Repros Therapeutics, Inc. :RPRX-US: Earnings Analysis: Q2, 2016 By the Numbers : September 27, 2016
    Capital Cube58 minutes ago

    Repros Therapeutics, Inc. :RPRX-US: Earnings Analysis: Q2, 2016 By the Numbers : September 27, 2016

    Categories: Yahoo Finance Get free summary analysis Repros Therapeutics, Inc. reports financial results for the quarter ended June 30, 2016. Analysis Summary numbers: Revenues of USD 0 million, Net Earnings of USD -4.28 million. The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless. RPRX-US‘s earnings ... Read more (Read more...)

  • GlobeNewswireyesterday

    FDA Schedules Advisory Committee Meeting To Discuss Secondary Hypogonadism

    Repros Therapeutics to participate as a Sponsor-- developing a therapy specifically designed to treat secondary hypogonadism. THE WOODLANDS, Texas, Sept. 26, 2016-- Repros Therapeutics Inc. ® today noted ...

  • Repros Seeks EU Approval for Secondary Hypogonadism Drug
    Zacks14 days ago

    Repros Seeks EU Approval for Secondary Hypogonadism Drug

    Repros Therapeutics Inc. (RPRX) announced that the company's UK subsidiary, Renable Pharma Limited, has submitted a marketing authorization application to the European Medicines Agency for one of its pipeline candidate, enclomiphene.